Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharmaceuticals
Epic: CGS
News: Latest news
Web Site: CogState
Other Articles: 24-08-201010-06-201010-06-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power

After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
CogState

CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.

Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Otsuka, Servier, along with a number of other organisations.

CLICK HERE FOR FULL ANLAYSIS OF COGSTATE
Thursday, June 10, 2010

Cogstate forms joint venture with Oregon based investment group to target US sports market

company news image

CogState (ASX:CGS) announced today it has partnered with a Portland Oregon based investment group to form Axon Sports, LLC.

As part of the agreement, CogState will take a 50% stake in Axon Sports and will exclusively license its technology used to assess the cognitive condition of concussed athletes to Axon Sports, for use in the North American market.

In the US, there is a growing awareness of the dangers associated with concussions in sport, particularly due to high profile sports injuries to athletes playing American football in college and in the NFL.  There are also dangers to a return to sport by athletes suffering concussion.

Brad O’Connor, chief executive officer of CogState said of the deal: “We are very excited by this joint venture and the opportunities it will provide to health specialists and athletes in dealing with sports-related concussion injuries in North America.”

Axon Sports will launch a re-branded technology, based on CogState Sport, in August 2010 and will focus on the delivery of products to both protect and train athlete’s brains.

To date, CogState Sport has been used for almost 10 years by a small number of well regarded institutions and sporting organisations around the world.  Customers of CogState Sport include: Notre Dame University, University of Michigan, English Rugby League, English Jockey Club, and a number of Australian Football League, Australian Rugby League and Australian Rugby Union clubs.

Axon Sports will initially provide baseline and after-injury tests to young athletes across North America in ways that are easily accessible, convenient, affordable and understandable for all individuals.

Further details on the joint venture partners and the revamped cognitive testing product, including branding and marketing details, will be released in August 2010.

AddThis Feed Button
Register here to be notified of future CogState articles.

Other CogState news

More news ►

Investors interested in CogState recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.